FINWIRES · TerminalLIVE
FINWIRES

受美伊谈判陷入僵局影响,交易所交易基金和股指期货周四盘前走低。

-- 由于美伊谈判因霍尔木兹海峡持续封锁而陷入僵局,周四盘前交易中,标普500指数ETF(SPDR S&P 500 ETF Trust,SPY)下跌0.1%,景顺QQQ ETF(QQQ)下跌0.2%。 美国股指期货也走低,标普500指数期货下跌0.4%,道琼斯工业平均指数期货下跌0.6%,纳斯达克指数期货下跌0.4%。 美国首次申请失业救济人数为21.4万人,高于预期的21万人和前值20.8万人。 芝加哥联邦储备银行3月份全国经济活动指数从2月份的0.03降至-0.20,低于彭博社截至美东时间上午7:35汇总的分析师调查结果,此前市场预期降幅为-0.13。 标普全球4月份制造业和服务业状况初值将于美东时间上午9:45公布,随后将于美东时间上午10:30公布每周天然气库存数据。 堪萨斯城联储4月份制造业指数将于美东时间上午11:00公布。 盘前交易中,比特币下跌1.6%。加密货币ETF方面,ProShares比特币策略ETF (BITO)下跌1.7%,以太坊ETF (EETH)下跌3.3%,比特币和以太坊市值加权ETF (BETH)下跌0.02%。 强势板块: 能源 iShares 美国能源 ETF (IYE) 上涨 0.03%,而 State Street 能源精选行业 SPDR ETF (XLE) 上涨 0.4%。 Helix Energy Solutions (HLX) 股价在开盘前上涨超过 8%,此前该公司同意以全股票交易的方式与 Hornbeck Offshore Services 合并,组建一家综合性海上服务公司。 涨跌板块: 医疗保健 State Street 医疗保健精选行业 SPDR ETF (XLV) 下跌 0.04%,Vanguard 医疗保健指数基金 (VHT) 下跌 0.3%,而 iShares 美国医疗保健 ETF (IYH) 未进行交易。iShares 生物技术 ETF (IBB) 下跌 1.2%。 赛诺菲 (SNY) 股价在盘前交易中上涨超过 3%,此前该公司公布了第一季度调整后收益和销售额均高于预期。 金融板块 道富金融精选行业SPDR ETF (XLF)上涨0.2%。Direxion每日3倍做多金融ETF (FAS)上涨0.4%,而其对应的做空金融ETF,Direxion每日3倍做空金融ETF (FAZ)下跌0.1%。 KB金融集团(KB)股价在盘前交易中上涨超过2%,此前该公司公布了第一季度盈利和营收均高于预期。 工业板块 道富工业精选行业SPDR ETF (XLI)上涨0.04%,而先锋工业指数基金(VIS)上涨0.7%,iShares美国工业ETF (IYJ)下跌0.4%。 联合太平洋铁路公司(UNP)股价在盘前交易中上涨超过2%,此前该公司公布了第一季度盈利和营业收入。 消费板块 道富消费必需品精选行业SPDR ETF (XLP) 上涨0.1%,先锋消费必需品指数基金ETF (VDC) 下跌0.3%。iShares美国消费必需品ETF (IYK) 未成交。道富可选消费精选行业SPDR ETF (XLY) 下跌0.5%。VanEck零售ETF (RTH) 和道富SPDR标普零售ETF (XRT) 未成交。 特斯拉 (TSLA) 股价在盘前下跌超过2%,此前该公司隔夜公布了第一季度财报,投资者关注其规模庞大的资本支出预期。 科技板块 道富科技精选行业SPDR ETF (XLK) 上涨0.4%,iShares美国科技ETF (IYW) 持平,而iShares扩展科技行业ETF (IGM) 下跌0.9%。在半导体ETF中,道富SPDR标普半导体ETF (XSD)上涨0.04%,而iShares半导体ETF (SOXX)上涨0.9%。 周四盘前交易中,英特尔(INTC)股价上涨超过1%,此前特斯拉(TSLA)首席执行官埃隆·马斯克表示,他计划在其位于德克萨斯州奥斯汀的Terafab先进人工智能项目中采用英特尔即将推出的14A工艺制造芯片。 大宗商品 纽约商品交易所近月合约美国西德克萨斯中质原油上涨0.2%,至每桶93.17美元。天然气上涨0.1%,至每百万英热单位2.73美元。美国石油基金(USO)上涨0.1%,而美国天然气基金(UNG)下跌0.4%。 纽约商品交易所(Comex)5月黄金期货价格下跌0.4%,至每盎司4734.40美元。白银期货价格下跌3.1%,至每盎司76.11美元。SPDR黄金信托基金(GLD)下跌0.3%,iShares白银信托基金(SLV)下跌1.8%。

Related Articles

Asia

Fadu Returns to Profit in Q1 as Sales Triple; Shares Jump 14%

Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.

$KOSDAQ:440110
Asia

ASX Biggest Losers

Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07

$^AXJO$ASX:COH$ASX:EVT$ASX:NXG$ASX:ORG$ASX:PDN$ASX:RHC$ASX:SX2$ASX:TLX$ASX:TUA$ASX:WTC
Asia

Sun Pharmaceutical to Acquire US-Based Organon in $11.8 Billion Deal

Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.

$BOM:524715$NSE:SUNPHARMA